COVID-19 and Cancer Resources
Kidney Cancer Journal 55
to be standardized in the management of immune-related
toxicities. In addition, due consideration should be
given for effective protocol design including endpoint
choice, and methods used for treatment response to
avoid some pitfalls.
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J
Clin. 2019;69(1):7-34.
2. Czarnecka AM, Kornakiewicz A, Kukwa W, Szczylik C. Frontiers in
clinical and molecular diagnostics and staging of metastatic clear cell
renal cell carcinoma. Future Oncol. 2014;10(6):1095-1111.
3. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC.
Results of treatment of 255 patients with metastatic renal cell carcinoma
who received high-dose recombinant interleukin-2 therapy. J
Clin Oncol. 1995;13(3):688-696.
4. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial
of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon
in patients with metastatic renal cell carcinoma. J Clin Oncol.
2005;23(1):133-141.
5. Wang J, Li X, Wu X, et al. Role of immune checkpoint inhibitorbased
therapies for metastatic renal cell carcinoma in the first-line setting:
A Bayesian network analysis. EBioMedicine. 2019;47:78-88.
6. Jonasch E. Implications of VHL-HIF pathway dysregulation in renal
cell carcinoma: current therapeutic strategies and challenges. Kidney
Cancer Journal. 2020;18(1):6-10.
7. Leite KR, Reis ST, Junior JP, et al. PD-L1 expression in renal cell carcinoma
clear cell type is related to unfavorable prognosis. Diagn Pathol.
2015;10:189.
8. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus
Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;
373(19):1803-1813.
9. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab
versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J
Med. 2018;378(14):1277-1290.
10. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation
immunotherapy—inhibiting programmed death-ligand 1 and programmed
death-1. Clin Cancer Res. 2012;18(24):6580-6587.
11. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab
versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med.
2017;377(19):1824-1835.
12. Choueiri TK, Fishman MN, Escudier B, et al. Immunomodulatory
Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer
Res. 2016;22(22):5461-5471.
13. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint
blockade. Science. 2018;359(6382):1350-1355.
14. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab
and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J
Med. 2015;373(1):23-34.
15. Jonasch E. NCCN Guidelines Updates: Management of Metastatic
Kidney Cancer. J Natl Compr Canc Netw. 2019;17(5.5):587-589.
16. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus
Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med.
2019;380(12):1116-1127.
17. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus
Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380
(12):1103-1115.
18. Kwilas AR, Donahue RN, Tsang KY, Hodge JW. Immune consequences
of tyrosine kinase inhibitors that synergize with cancer immunotherapy.
Cancer Cell Microenviron. 2015;2(1).
19. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for Metastatic
Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin
Oncol. 2015;33(13):1430-1437.
20. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab
versus sunitinib in patients with previously untreated metastatic renal
cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised
controlled trial. Lancet. 2019;393(10189):2404-2415.
21.Amin A, Plimack ER, Ernstoff MS, et al. Safety and efficacy of
nivolumab in combination with sunitinib or pazopanib in advanced
or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother
Cancer. 2018;6(1):109. KCJ
KCJ is committed to provide the latest information and
resources to its readers and the larger oncology community
to ensure that cancer patients receive high-quality care.
In line with this, we have compiled various resources that
provide information to support patients with cancer,
clinicians, and researchers within the cancer care delivery
team. As we update the KCJ webpage on a regular basis,
please continue to check back for the most current
information here: kidney-cancer-journal.com/covid-19.html
/covid-19.html